GABA (gamma-aminobutyric acid) is a neurotransmitter that acts as an inhibitory chemical messenger in the central nervous system. It functions by binding to specific receptors in the brain, reducing neuronal activity and promoting relaxation. GABA is used in the treatment of various disease indications, including anxiety disorders such as generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder. It is also utilized as a natural sleep aid to alleviate insomnia symptoms and improve sleep quality. According to the World Health Organization (WHO), anxiety disorders affect approximately 3.6% of the global population, with Europe and the United States experiencing similar prevalence rates. In Europe, it is estimated that around 60 million individuals are affected by anxiety disorders. In the United States, anxiety disorders are the most common mental illnesses, affecting approximately 40 million adults. Insomnia, another indication for GABA, affects about 30% of the European population and over 35% of adults in the United States, as reported by WHO.
The growth of the GABA market is driven by several factors, including the increasing awareness among consumers about the benefits of GABA in promoting relaxation and reducing anxiety and sleep-related issues. Companies such as Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Balance Therapy, Allos Pharma, Cerevel Therapy, UCB, Roche, Nobias Therap, Bausch Health, Royalty, RVL Pharma, Neurelis, Marinus, Asarina Pharma, Aquestive, Remedica, Acorda, XWPharma, BioLineRx, Takeda, and J&J cater this category. Moreover, many companies are coming up with new molecules in this space. For instance, UCB is one such company that is currently conducting a clinical trial of the drug AZ022 for the treatment of epilepsy.
GABA Market Key Developments:
- In Oct 2022, Neuraxpharm launched Midazolam for epilepsy (In adolescents, In children, In infants) in Switzerland.
- In Jan 2021, Neuraxpharm launched Midazolam for Status epilepticus in Japan.
Approved GABA molecules
- Midazolam hydrochloride
- Gabapentin
- Topiramate
- Baclofen
- Lorazepam
- ByFavo (remimazolam)
- Isoflurane
- Alprazolam
- sodium Valproate
- Diazepam
- Eszopiclone
- divalproex Sodium XR
- Qutenza (capsaicin)
- Phenobarbital
- Penthrox (methoxyflurane)
- Horizant (gabapentin enacarbil XR)
- Clonazepam
- Vigabatrin
- Clobazam
- Potiga (retigabine)
- Campral EC (acamprosate delayed release)
- Temazepam
- Gralise (gabapentin)
- Ztalmy (ganaxolone oral)
- Zulresso (brexanolone)
- Zolpidem ER
- Adlea (capsaicin)
- Xcopri (cenobamate)
- Diacomit (stiripentol)
- Lyrica CR (pregabalin CR)
- Seizalam (midazolam intramuscular)
- Tarlige (mirogabalin)
- Lendormin (brotizolam)
- Zaleplon
- Thiocolchicoside
- Oxazepam
- Diastat (diazepam rectal gel)
- Natroba (spinosad)
- Stavzor (valproic acid oral)
- Primidone
- Zolpidem sublingual
- Buccolam (midazolam oromucosal solution)
- Nayzilam (midazolam intranasal)
GABA Pipeline Molecules
- Ciprofol injectable emulsion (HSK3486)
- Gaboxadol (OV101)
- Remimazolam tosylate (HR-7056)
- BAER-101
- Arbaclofen (STX209)
- Darigabat (CVL-865)
- Padsevonil (UCB0942)
- Basmisanil (RG1662)
- Zuranolone (SAGE-217)
- Staccato alprazolam (AZ-002)
- Arbaclofen placarbil (XP 19986)
- PRAX-114
- Fasoracetam (NB-001)
- Pentylenetetrazole (BTD-001)
- BL-1020
- JNJ-26489112
- Sepranolone (UC1010)
- XW10172
- EQU-001
- SAGE-324
- Acamprosate controlled-release (SNC-102)
- Golexanolone (GR3027)
- Lotilaner oral (TP-05)
- Sodium oxybate ER (FT218)
- EVT201
- RL-007
- Baclofen extended-release (IPX056)
Clinical Activity and Development of GABA
In the GABA space, more than 20 companies are conducting >200 clinical trials in this category of drugs. For instance,
- In Aug 2021, Grunenthal initiated the phase III AV001 trial of Qutenza for Neuropathic pain (post-surgical neuropathic pain) (PSNP) in the Europe and the USA.
- In May 2023, Seaside Therapeutic’s Arbaclofen entered phase III trials for Fragile X syndrome (In children) in the USA
|
Product Name |
Total Studies |
|
Ciprofol injectable emulsion (HSK3486) |
45 |
|
Gaboxadol (OV101) |
24 |
|
Remimazolam tosylate (HR-7056) |
21 |
|
BAER-101 |
16 |
|
Arbaclofen (STX209) |
16 |
|
Darigabat (CVL-865) |
15 |
|
Padsevonil (UCB0942) |
15 |
|
Basmisanil (RG1662) |
14 |
|
Zuranolone (SAGE-217) |
14 |
|
Staccato alprazolam (AZ-002) |
12 |
|
Arbaclofen placarbil (XP 19986) |
9 |
|
PRAX-114 |
7 |
|
Fasoracetam (NB-001) |
7 |
|
Pentylenetetrazole (BTD-001) |
6 |
|
BL-1020 |
5 |
|
JNJ-26489112 |
5 |
|
Sepranolone (UC1010) |
5 |
|
XW10172 |
4 |
|
EQU-001 |
3 |
|
SAGE-324 |
3 |
Target Indication Analysis of GABA
GABA (gamma-aminobutyric acid) is a neurotransmitter that plays a crucial role in regulating brain activity and promoting relaxation. In the context of target indications, GABA is commonly used to alleviate symptoms associated with anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder. It is also utilized as a natural sleep aid to improve sleep quality and reduce insomnia symptoms. GABA's calming effects on the central nervous system make it a potential candidate for managing stress, promoting mental relaxation, and supporting overall mental well-being. Furthermore, ongoing research explores its potential therapeutic applications in conditions like epilepsy, depression, and ADHD, but further investigation is required for conclusive evidence.
GABA Market Regional Analysis
GABA Market
The global GABA market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The US market analysis of GABA indicates a steady growth trajectory. With a rising prevalence of anxiety disorders and sleep-related issues, there is an increasing demand for GABA-based pharmaceutical products. Additionally, the growing awareness among consumers about the potential benefits of GABA in promoting relaxation and mental well-being has further fueled market growth. Furthermore, favorable reimbursement policies, extensive healthcare infrastructure, and a robust pharmaceutical industry in the US have contributed to the expansion of the GABA market. The availability of various product formulations, including oral supplements, capsules, and topical creams, has also broadened the consumer base and supported market growth. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for GABAs. On the other hand, the GABA market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the GABA market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
GABA drugs are used in the management of symptoms associated with anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder.
The growth of the GABA market is driven by several factors, including the increasing awareness among consumers about the benefits of GABA in promoting relaxation and reducing anxiety and sleep-related issues.
The major players in this space are Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Balance Therapy, Allos Pharma, Cerevel Therap, UCB, Roche, Nobias Therap, Bausch Health, Royalty, RVL Pharma, Neurelis, Marinus, Asarina Pharma, Aquestive, Remedica, Acorda, XWPharma, BioLineRx, Takeda, and J&J.
The GABA market faces restraints such as limited awareness among consumers about its potential benefits and effectiveness, as well as regulatory challenges and restrictions on its use in certain regions or jurisdictions, which hinder its widespread adoption and growth. Additionally, the availability of alternative products or treatments for anxiety and sleep disorders poses a competitive challenge to the GABA market.
- Pfizer
- Daiichi Sankyo
- Boehringer Ingelheim
- Balance Therap
- Allos Pharma
- Cerevel Therap
- UCB
- Roche
- Nobias Therap
- Bausch Health
- Royalty
- RVL Pharma
- Neurelis
- Marinus
- Asarina Pharma
- Aquestive
- Remedica
- Acorda
- XWPharma
- BioLineRx
- Takeda
- J&J